GU Cancers 2023 | IMvigor130: clinical implications and next steps
Aristotelis Bamias, MD, National and Kapodistrian University of Athens, Athens, Greece, discusses the clinical implications of the Phase III IMvigor130 (NCT03547973) trial evaluating atezolizumab with or without chemotherapy in metastatic urothelial carcinoma. The study found There was no difference OS results by PD-L1 status when patients had low or no expression of PD-L1, however, an overall-survival (OS) benefit was observed in patients with high expression of PD-L1. In patients who were ineligible for cisplatin, the OS benefit was significant, with a median OS of 18 months with atezolizumab versus 10 months with chemotherapy alone. The results of the trial enabled for the identification of a specific subset of patients who will benefit from the addition of atezolizumab to chemotherapy in the second-line setting. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
